H. A. Burris

1.8k total citations
57 papers, 770 citations indexed

About

H. A. Burris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, H. A. Burris has authored 57 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in H. A. Burris's work include Cancer Treatment and Pharmacology (22 papers), HER2/EGFR in Cancer Research (17 papers) and Colorectal Cancer Treatments and Studies (15 papers). H. A. Burris is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), HER2/EGFR in Cancer Research (17 papers) and Colorectal Cancer Treatments and Studies (15 papers). H. A. Burris collaborates with scholars based in United States, United Kingdom and Australia. H. A. Burris's co-authors include Suzanne F. Jones, J. R. Infante, J. C. Bendell, Daniel D. Von Hoff, Scott N. Holden, María Koehler, David R. Spigel, John Crown, M. Versola and Andrew G. Stead and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

H. A. Burris

57 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. A. Burris United States	17	534	271	218	119	92	57	770
R. Islam United States	7	531 1.0×	207 0.8×	277 1.3×	97 0.8×	132 1.4×	8	725
H.A. Burris United States	13	496 0.9×	316 1.2×	213 1.0×	111 0.9×	72 0.8×	63	679
Robert N. Raju United States	16	667 1.2×	284 1.0×	241 1.1×	181 1.5×	178 1.9×	30	985
Nishan Tchekmedyian United States	10	522 1.0×	297 1.1×	400 1.8×	73 0.6×	172 1.9×	17	795
A. Lambiase Italy	17	613 1.1×	297 1.1×	181 0.8×	146 1.2×	92 1.0×	55	899
Tetsuji Sawada Japan	20	392 0.7×	494 1.8×	138 0.6×	89 0.7×	199 2.2×	38	928
Sharon Wilks United States	16	688 1.3×	272 1.0×	405 1.9×	125 1.1×	236 2.6×	49	950
Noah Goodman United States	10	381 0.7×	116 0.4×	275 1.3×	76 0.6×	103 1.1×	12	646
Richard A. Michaelson United States	9	833 1.6×	168 0.6×	196 0.9×	389 3.3×	125 1.4×	18	1.0k
P.N. Munster United States	12	336 0.6×	307 1.1×	119 0.5×	49 0.4×	79 0.9×	18	584

Countries citing papers authored by H. A. Burris

Since Specialization

Citations

This map shows the geographic impact of H. A. Burris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. A. Burris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. A. Burris more than expected).

Fields of papers citing papers by H. A. Burris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. A. Burris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. A. Burris. The network helps show where H. A. Burris may publish in the future.

Co-authorship network of co-authors of H. A. Burris

This figure shows the co-authorship network connecting the top 25 collaborators of H. A. Burris. A scholar is included among the top collaborators of H. A. Burris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. A. Burris. H. A. Burris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pietanza, M. Catherine, David R. Spigel, Tyler M. Bauer, et al.. (2015). 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). European Journal of Cancer. 51. S712–S712. 12 indexed citations

Papadopoulos, Kyriakos P., David S. Mendelson, A. W. Tolcher, et al.. (2011). A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3075–3075. 19 indexed citations

Burris, H. A., Jordi Rodón, A.R. Abdul Razak, et al.. (2011). Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.. Journal of Clinical Oncology. 29(15_suppl). 3043–3043. 19 indexed citations

Donehower, Ross C., Martin Hill, Jessica Bowman, et al.. (2011). A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3091–3091. 7 indexed citations

Cervantes, Andrés, María Alsina, Josep Tabernero, et al.. (2011). Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology. 29(15_suppl). 3025–3025. 44 indexed citations

Raefsky, Eric, David R. Spigel, J. R. Infante, et al.. (2011). Phase II study of NK012 in relapsed small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). 7079–7079. 12 indexed citations

Infante, J. R., et al.. (2011). Axitinib inhibition of [¹⁸F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.. Journal of Clinical Oncology. 29(15_suppl). 3591–3591. 7 indexed citations

LoRusso, P., et al.. (2011). Pharmacokinetic and pathophysiologic covariates influencing treatment outcomes with T-DM1 in patients with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 633–633. 1 indexed citations

Peacock, N. W., DA Yardley, Carolyn B. Hendricks, et al.. (2011). Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial.. Journal of Clinical Oncology. 29(15_suppl). 1066–1066. 2 indexed citations

10.

Peacock, N. W., Suzanne F. Jones, Denise A. Yardley, et al.. (2010). A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.. Journal of Clinical Oncology. 28(15_suppl). 1115–1115. 11 indexed citations

11.

Jones, Suzanne F., William C. Zamboni, H. A. Burris, et al.. (2009). Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2547–2547. 5 indexed citations

12.

Crown, John, H. A. Burris, Frances M. Boyle, et al.. (2008). Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment. 112(2). 317–325. 75 indexed citations

13.

Badarinath, Suprith, et al.. (2008). A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): Preliminary results. Journal of Clinical Oncology. 26(15_suppl). 575–575. 4 indexed citations

14.

Cohen, Richard B., Suzanne F. Jones, Margaret von Mehren, et al.. (2008). Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2520–2520. 11 indexed citations

15.

Spigel, David R., John D. Hainsworth, Denise A. Yardley, et al.. (2007). Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18130–18130. 7 indexed citations

16.

Burris, H. A., Suzanne F. Jones, David W. Hein, et al.. (2007). Phase I/II dose-escalation trial of amonafide for treatment of advanced solid tumors: Genotyping to optimize dose based on polymorphic metabolism. Journal of Clinical Oncology. 25(18_suppl). 2503–2503. 3 indexed citations

17.

Peacock, N. W., David R. Spigel, John D. Hainsworth, et al.. (2006). A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17054–17054. 3 indexed citations

18.

Seiden, Michael V., H. A. Burris, U. Matulonis, et al.. (2005). A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology. 23(16_suppl). 3151–3151. 8 indexed citations

19.

Spector, Nelson, Wen Xia, H. A. Burris, et al.. (2004). Modulation of tumor growth and survival pathways in cancer patients treated with GW572016. Journal of Clinical Oncology. 22(14_suppl). 3003–3003. 1 indexed citations

20.

Rothenberg, Mace L., A. Sharma, Geoffrey R. Weiss, et al.. (1998). Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Annals of Oncology. 9(7). 733–738. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact